Document:

Exhibit

EXHIBIT 4(b)

DESCRIPTION OF THE REGISTRANT’S SECURITIES 
REGISTERED PURSUANT TO SECTION 12 OF 
THE SECURITIES EXCHANGE ACT OF 1934

DESCRIPTION OF CAPITAL STOCK
The Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”) of SIGA Technologies, Inc. (the “Company”) authorizes 600,000,000 shares of common stock, par value $0.0001 per share (“common stock”), and 20,000,000 shares of preferred stock, par value $0.0001 per share (“preferred stock”).
The Company has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock.  No preferred stock is outstanding.
Common Stock and Preferred Stock
Dividend Rights.  The holders of the common stock and the preferred stock shall be entitled to dividends, when, as and if declared by the board of directors of the Company, payable at such time or times as the board of directors may determine.
Terms of conversion.  Our common stock has no conversion rights.  The board of directors shall have the authority to fix by resolution the voting powers (full, limited, multiple, fractional or none), designations, preferences, qualifications, privileges, limitations, restrictions, options, conversion rights and other special or relative rights of the preferred stock or any class or series thereof prior to or concurrently with the issuance of such shares.
Redemption and Sinking Fund Provisions.  There are no redemption or sinking fund provisions applicable to the common stock.  All outstanding shares of common stock are fully paid and nonassessable.
Voting Rights.  Each holder of common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders.  The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and, as a consequence, minority stockholders will not be able to elect directors on the basis of their votes alone.
At any meeting of stockholders, all matters other than the election of directors, except as otherwise provided by the Certificate of Incorporation, the by-laws or any applicable law, shall be decided by the affirmative vote of a majority in voting power of shares of stock present in person or represented by proxy and entitled to vote thereon.
Liquidation Rights.  In the event of a liquidation, dissolution or winding up of the Company, holders of our common stock would be entitled to share ratably in all assets remaining after payment of liabilities and the satisfaction of any liquidation preference of any then outstanding series of preferred stock.
Preemption Rights.  Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities.
Our Certificate of Incorporation allows our board of directors to fix the voting powers, designations, preferences, rights and qualifications, limitations or restrictions of the preferred stock without any further vote or action by the stockholders.  The rights of the holders of common stock will be subject to, and could be adversely affected by, the rights of the holders of any preferred stock that we may issue in the future.  The issuance of preferred stock, while providing desirable flexibility in connection with our future activities, could also have the effect of making it more difficult for a third party to acquire a majority of our outstanding voting stock, thereby delaying, deferring or preventing a change of control.Exhibit

Exhibit 10(rr)

Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.  Information that has been omitted has been noted in this document with a placeholder identified by the term “{redacted}”.  

	
														
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	1. CONTRACT ID CODE
	PAGE OF PAGES

	 
	 
	1
	4

	2. AMENDMENT/MODIFICATION NO.
P00020
	3. EFFECTIVE DATE
See Block 16C
	4. REQUISITION/PURCHASE REQ. NO.

	5. PROJECT NO. (If applicable)

	6. ISSUED BY   CODE
	HHS/OS/ASPR/BARDA
	7. ADMINISTERED BY (If other than Item 6)   CODE
	ASPR-BARDA02

	HHS/OS/ASPR/BARDA 
330 Independence Ave., S.W. 
Room 640-G 
Washington DC 20201
	ASPR-BARDA 
330 Independence Ave, SW, Rm G640 
Washington DC 20201

	8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)
	(x)
	9A. AMENDMENT OF SOLICITATION NO.

	SIGA TECHNOLOGIES, INC.   1385150
	 
	 

	SIGA TECHNOLOGIES, INC.                35 E 6
	 
	9B. DATED (SEE ITEM 11)

	35 E 62ND ST
	 
	 

	NEW YORK NY 100658014
	x
	10A. MODIFICATION OF CONTRACT/ORDER NO. 
HHSO100201100023C

	 
	 
	 

	CODE  
1385150
	FACILITY CODE
	 
	10B. DATED (SEE ITEM 13)
06/01/2011

	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

	☐   The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers   ☐is extended.  ☐ is not extended.
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)
See Schedule

	13. THIS ITEM ONLY APPLIES TO MODIFICATIONS OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK ONE
	A.   THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	 

	 
	B.   THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

	X
	C.   THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
FAR 43.103(a) - Bilateral modification between the parties

	 
	D.   OTHER (Specify type of modification and authority)

	E. IMPORTANT:
	Contractor   ☐ is not   ☒ is required to sign this document and return   1   copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

	Tax ID Number: 13-3864870
DUNS Number: 932651516
Modification 20 accomplishes the following administrative actions:
1.)   Incorporates Subsection B.4.j outlining reconciliation of contract budget and status of CLINs
2.)   Incorporates Subsection B.4.d.11 increasing Contracting Officer’s Authorization threshold from $100,000 to $250,000
3.)   Section J – Attachment 1 – Statement of Work – Incorporates additional language into
Continued ...

	Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	15A. NAME AND TITLE OF SIGNER (Type or print)
Dennis E. Hruby, Chief Scientific Officer
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
GEORGE J. KEANE

	15B. CONTRACTOR/OFFEROR
/s/ Dennis E. Hruby   
(Signature of person authorized to sign)
	15C. DATE SIGNED
19 November 2019
	16B. UNITED STATES OF AMERICA
/s/ George J. Keane   
(Signature of Contracting Officer)
	16C. DATE SIGNED
20 November 2019

		
	Previous edition unusable
	STANDARD FORM 30 (REV. 11/2016) 
Prescribed by GSA FAR (48 CFR) 53.243

	
									
	CONTINUATION SHEET
	REFERENCE NO. OF DOCUMENT BEING CONTINUED
HHSO100201100023C/P00020
	PAGE OF

	2
	4

	NAME OF OFFEROR OR CONTRACTOR
SIGA TECHNOLOGIES, INC. 1385150

	ITEM NO.
	SUPPLIES/SERVICES
	QUANTITY
	UNIT
	UNIT PRICE
	AMOUNT

	(A)
	(B)
	(C)
	(D)
	(E)
	(F)

	 
	CLIN 0003 of the Statement of Work
3.)   Revises Subsection G.1 changing the Contracting Officer to George J. Keane, Jr.
4.)   Revises Subsection G.1 changing the Project Officer / Contracting Officer’s Representative to David Simon, Ph.D.
See supplemental pages for additional information. All other terms and conditions of contract HHSO100201100023C remain unchanged.
Period of Performance:  05/15/2011 to 12/30/2020
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

		
	NSN 7540-01-152-8067
	OPTIONAL FORM 336 (4-86) 
Sponsored by GSA 
FAR (48 CFR) 53.110

Beginning with the effective date of this modification, the U.S. Government and Contractor mutually agree as follows:
		
	1)
	Incorporate SUBSECTION B.4.j – Is incorporated into the contract and the following language inserted into that subsection:

At the close of FY2018, expiring funds were removed from the contract via Contract Modification 0018 (MOD 18). The sum of funds expiring from the contract differed between SIGA’s records and what was presented in MOD 18 by $144,272.10 (see below). The source of the mismatched quantities could not be identified.
Expected de-Obligation per SIGA    -$426,647.00 
Actual de-obligation per MOD 18     -$570,919.10     
Difference    $144,272.10
However, Contractor (“SIGA”) and U.S. Government (“BARDA”) are in agreement that the work carried out under Contract CLINs 0001, 0002, 0011, 0012, and 0013 are complete and all invoices associated with these CLINs have been paid by BARDA. These CLINs show a $0 (zero) balance. Further, SIGA and BARDA are in agreement that as of the start of FY 2019-2020, the funds remaining on the contract (i.e. funds for which SIGA has not yet invoiced the government) total $4,006,492 (see table).
	
					
	CLIN
	Scope
	Budget ($)
	Status
	Remaining Budget ($)

	1
	{redacted}
	9,346,886
	Complete
	0

	2
	{redacted}
	11,625,891
	Complete
	0

	3
	{redacted}
	3,442,707
	Ongoing
	1,721,353

	4
	{redacted}
	1,716,198
	Ongoing
	1,102,344

	5
	{redacted}
	959,798
	Ongoing
	594,591

	6
	{redacted}
	2,886,375
	Ongoing
	200,642

	7
	{redacted}
	3,742,304
	Ongoing
	48,496

	8
	{redacted}
	1,944878
	Ongoing
	339,066

	11
	{redacted}
	177,104
	Complete
	0

	12
	{redacted}
	769,814
	Complete
	0

	13
	{redacted}
	2,439,274
	Complete
	0

	Remaining funds as of 01 October 2019 (FY19-20)
	4,006,492

		
	2)
	Incorporate SUBSECTION B.4.d.11 – Is incorporated into the contract and language inserted into that subsection increasing Contracting Officer’s Authorization (COA) threshold from $100,000 to $250,000 as follows:

Award of any FFP subcontract or FFP consulting agreement in excess of $250,000 or any cost reimbursement, labor hour subcontract or consulting agreement funded under a Cost Plus Fixed Fee

CLIN shall not proceed without the prior written consent of the Contracting Officer via a Contracting Officer Authorization (COA) Letter upon review of the supporting documentation required by FAR Clause 52.244-2, Subcontracts. After receiving written consent of the subcontract by the Contracting Officer, a copy of the signed, executed subcontract and consulting agreement shall be provided to the Contracting Officer.
		
	3)
	SECTION J – ATTACHMENT 1 – STATEMENT OF WORK

The Statement of Work (SOW) applicable to CLIN 0003 incorporates the following new language:
Based on FDA feedback, CLIN 0003, will include additional regulatory activities and labor in support of the IV product including post NDA filing of FDA Information Requests, FDA inspections, and IND and NDA life-cycle management submissions.
		
	4)
	SUBSECTION G.1 PROJECT OFFICER 

The Contracting Officer is hereby changed to:
George J. Keane, Jr. 
Team Lead / Contracting Officer – CBRN, Flu, PBS 
Station Support & Administrative Branch 
Division of Contracts Management & Acquisition 
Biomedical Advanced Research & Development Authority (BARDA) 
Office of Secretary for Preparedness & Response (ASPR) 
Department of Health and Human Services
Mailing Address: 
{redacted}
The Project Officer (Contracting Officer’s Representative) is hereby changed to:
David Simon, Ph.D. 
Health Scientist / Antiviral Antitoxin Branch 
Division of CBRN Countermeasures 
Biomedical Advanced Research & Development Authority (BARDA) 
Office of Secretary for Preparedness & Response (ASPR) 
Department of Health and Human Services
Mailing Address: 
{redacted}
END OF MODIFICATION 20 of HHSO100201100023C

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]